Celyad Oncology SA (EBR: CYAD)

Celyad Oncology Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 20, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	29	16	11	79	92	135
Market Cap Growth	-1.65%	41.33%	-85.60%	-13.96%	-31.75%	-31.74%
Enterprise Value	23	12	-1	76	69	107
Last Close Price	0.69	0.39	0.51	3.52	6.62	9.70
PS Ratio	161.11	158.40	-	-	18459.66	22540.12
PB Ratio	8.78	2.56	2.65	1.82	2.98	2.96
P/TBV Ratio	3.58	2.58	2.96	10.00	-	13.49
EV/Sales Ratio	78.53	114.87	-	-	13862.06	17751.12
Debt / Equity Ratio	0.30	0.17	0.06	0.06	0.12	0.10
Asset Turnover	0.01	0.01	-	-	0.00	0.00
Quick Ratio	3.03	3.34	1.31	2.34	1.53	3.53
Current Ratio	3.59	3.79	1.42	2.48	1.67	3.59
Return on Equity (ROE)	-361.90%	-159.08%	-170.72%	-71.05%	-44.91%	-56.58%
Return on Assets (ROA)	-38.87%	-33.03%	-31.92%	-23.32%	-21.04%	-20.02%
Return on Capital (ROIC)	-167.43%	-99.63%	-62.57%	-42.08%	-38.76%	-34.39%
Earnings Yield	-31.88%	-52.29%	-358.06%	-33.38%	-18.64%	-21.17%
FCF Yield	-35.88%	-99.65%	-246.08%	-33.96%	-30.14%	-21.16%
Buyback Yield / Dilution	-55.53%	-13.84%	-44.80%	-11.92%	-11.33%	-12.39%
Total Shareholder Return	-55.53%	-13.84%	-44.80%	-11.92%	-11.33%	-12.39%

Source: S&P Capital IQ. Standard template. Financial Sources.